- Risks
- Debt taken on for the GOJO and Glad joint-venture buyouts pushed leveragenet debt to about 4.42 times fiscal 2026 EBITDA, above the 3.6 times expected when the GOJO deal was signed, because EBITDA itself has fallen. S&P has already cut Clorox's credit rating once. Management's plan to return to about 2.5 times leverage by the end of calendar 2027 depends on earnings actually recovering.
CEO Linda Rendle announced in May 2026 that she will step down for health reasons once the board finds a successor. This leadership transition adds execution risk at the same time Clorox is integrating GOJO and stabilizing its new SAP system.
Private-label pressure is not spread evenly across Clorox's business. The Household segment, which includes trash bags and cat litter, earns only a 10.7% margin and 16% of segment profit despite being Clorox's second-largest segment by sales. Further private-label gains here would hurt profit more than in Clorox's stronger categories.
A California judge let most of Clorox's $380 million lawsuit against Cognizant proceed in March 2026, but no trial date has been set. This is realistic multi-year litigation, not a near-term payout, and Clorox has recovered only a fraction of its claimed damages from insurance so far.
The options market already prices unusually high volatility into Clorox shares, well above a typical staples stock. This reflects real uncertainty about leverage, the open CEO search, and whether the FY2027 rebound holds up, with the next test being Clorox's Q1 fiscal 2027 earnings report, expected in early November 2026.
- Balance sheet
- Clorox borrowed to buy GOJO for about $2.15 billion in April 2026. Most of its debt is unsecured debt of the parent company. At June 30, 2026, debt was $5.07 billion, plus $530 million of lease liabilities. $3.98 billion was fixed-rate senior notes, including $1.5 billion of new notes from May 2026, due 2031 to 2036. $1.09 billion was commercial paper at floating rates. Cash was only $143 million. Thus net debt before leases was about $4.9 billion, about 4.2 times fiscal 2026 EBITDA of $1.17 billion. EBIT of $921 million covered interest expense of $130 million about 7 times. GOJO added profit for only one quarter. Interest cost will rise in fiscal 2027, because the new debt is outstanding for the full year. Long-term debt maturities are small until $901 million in fiscal 2028. $1.96 billion of revolving credit lines were undrawn, but $764 million of that amount expires on March 5, 2027. S&P cut the long-term rating to BBB from BBB+ in February 2026, and Moody's rated Clorox Baa1 at June 30, 2026. A cut below investment grade would let derivative counterparties ask for full collateral. Equity that Clorox shareholders own was only $90 million because of years of buybacks. This is not a solvency problem by itself. But dividends of $602 million were larger than fiscal 2026 free cash flow of $405 million before the one-time $476 million Glad payment. The debt limits Clorox's choices. The cash must go to the dividend and to debt reduction toward the 2.5 times target by the end of calendar 2027. This leaves little room for buybacks or another deal.
As of 2026-06-30.
- Checkpoints
- Nov 3, 2026 (estimate): Fiscal Q1 2027 earnings: sales rebound and leverage. Pending. Watch: Organic sales growth on track for the 3.5% to 4.5% fiscal 2027 range and lower net debt pass; another sales decline or higher leverage fails.
Feb 2027 (estimate): Fiscal Q2 2027 earnings: margin repair and GOJO. Pending. Watch: Gross margin growth and GOJO profit in line with plan pass; a guidance cut or a new credit downgrade fails.
Q1 2027 (estimate): Board names a permanent CEO. Pending. Watch: A named successor with a clear plan for GOJO and debt reduction passes; a search that continues past fiscal Q3 2027 fails.
Dec 2027 (estimate): Leverage back near 2.5 times EBITDA. Pending. Watch: Net leverage near 2.5 times by the end of calendar 2027 passes; leverage still above 3.5 times fails.